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CRC; patients are now expected to survive longer and have the potential to expe-
rience various side effects related to chemotherapy. Knowing how patients value
the outcomes and preferences of treatment options for CRC is important to oncol-
ogists and policy makers in planning and introducing treatment interventions.
METHODS:Qualitative interviewswith 27 CRC patientswere used to identify seven
treatment attributes and their levels with regard to chemotherapy for CRC, for
inclusion in a discrete choice experiment (DCE) survey. These attributes were: life
expectancy, fatigue, diarrhoea, oral symptoms, hair loss, pain, and nausea and
vomiting. The survey was completed by 150 CRC patients to assess their prefer-
ences for the treatment of CRC. A conditional logit model was used to analyse the
data using STATA v9.0. RESULTS: The results of the DCE survey showed that, with
the exception of oral symptoms, all other attributes were found to be important
factors when it came to treatment decisions made by participants. The results
confirmed the prior hypothesis about the directions of attributes. For example, life
expectancy had a positive coefficient value, which indicated that the greater the
life expectancy, the more likely a participant would be to prefer that treatment. In
contrast, the negative values for pain, diarrhoea, fatigue, nausea and vomiting, and
hair loss indicate that participantswould not prefer a treatment that produce these
toxicities. Patients preferred to trade-off life expectancy for the reduction in the
likelihood of specific side effects. CONCLUSIONS: The results indicate the types of
risks and benefits that are important to patients with treatments for CRC. The
findings are likely to assist health care professionals in prioritising issues that need
to be discussed during treatment consultations.
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OBJECTIVES: This research study aimed to investigate the perception of cancer
patients towards the use of Traditional & Complementary Medicines (T&CM) for
cancer treatment. METHODS: Qualitative methodology was adapted to collect in-
depth information from consented cancer patients who were recruited from the
oncology wards at Penang General Hospital from May 2010 to August 2010. After
obtaining institutional ethical approval, patients with different types of cancer and
stages from the three major ethnic groups in Malaysia namely Malay, Chinese and
Indians were approached. Twenty semi-structured interviews were conducted af-
ter obtaining informed consent. All interviews were audiotaped, transcribed ver-
batim and translated into English for thematic content analysis. RESULTS: A total
of 3 themes were identified from the interview analysis: 1) positive attitude to-
wards spiritual ways of healing for cancer treatment, 2) concerns about the safety
and efficacy of T&CM for cancer treatment; and 3) concerns towards the legitimacy
of the claims made by traditional practitioners. Patients were willing to try non-
invasive treatments such as prayers, spiritual and faith healing therapies for can-
cer treatment. Lack of a fixed dosing system, unknown side effects and substan-
dard methods of preparation were other reported reasons for rejecting T&CM use.
The respondents showed a great concern towards the authenticity of claimsmade
by traditional practitioners and the majority demanded that true and fair claims
should be made by traditional practitioners in order to help patients in making
decisions regarding cancer therapy. CONCLUSIONS: The respondents in this study
did not appear to have attitudes regarding TCM that could lead to treatment delays
but thismay be due to the samplingmethod. Future studies are needed to evaluate
perceptions among thosewhohave defaulted treatment at any stage of cancer. The
current study has contributed to a greater understanding of the use of T&CM
among cancer patients that are not defaulting treatment.
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OBJECTIVES: New treatment improves efficacy and often has toxicities. The qual-
ity-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis in-
corporates survival, toxicities and quality of life into a single metric providing an
integrated measure of clinical benefit. Objective of this study was to use Q-TWiST
analysis comparing quality-adjusted survival between patients with chemo-re-
fractory wild-type KRAS metastatic colorectal cancer (mCRC) receiving panitu-
mumab  best supportive care (BSC) versus BSC alone. Because the trial design
allowed patients on BSc arm to receive panitumumab after disease progression,
whichmay have confounded overall survival (OS), the focus of this analysis was on
progression-free survival (PFS).METHODS: The time spent in the toxicity (grade 3
or 4 adverse events; TOX), time without symptoms of disease or toxicity (TWiST),
and relapse (after disease progression; REL) states were estimated, and adjusted
using utility weights derived from patient-reported EQ-5D measures. Quality-ad-
justed PFS was when the utility for REL was zero in the Q-TWiST analysis. Sensi-
tivity analyses were performed in which utility weights (varying from 0 to 1) were
applied to TOX and REL health states. RESULTS: The trial included 463 patients,
KRAS status ascertained in 427 (92%) of patients. Of these, 243 (57%) having wild-
type KRAS tumours (124 panitumumab BSC, 119 BSC alone) were included in the
analysis. Statistically significant difference between groups in quality-adjusted PFS
favoured panitumumab  BSC (12.3 weeks versus 5.8 weeks, respectively,
p0.0001). The difference continued to favour panitumumab  BSC for all hypo-
thetical utility weights applied to the TOX health state in sensitivity analyses.
Although OS was confounded by 76% of patients in the BSC alone arm receiving
panitumumab after disease progression, the difference in quality-adjusted OS was
also statistically significant and favoured panitumumab BSC. CONCLUSIONS: In
patients with chemo-refractory wild-type KRAS mCRC, panitumumab  BSC sig-
nificant improved quality-adjusted survival compared with BSC alone.
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OBJECTIVES: Our objective was to understand how oncologists view patient-re-
ported outcomes (PROs) and whether PRO data influences their clinical decision
making. METHODS: Twenty oncologists participated in 1 of 4 semi-structured fo-
cus groups (5 per group). Topics for discussion included: relative value of PROs
compared to other efficacy outcomes, impact of PROs on clinical decision making,
and interpretation of PRO data. Transcripts were analyzed using Atlas.ti software.
RESULTS: The oncologists represented a diverse sample in terms of gender (55%
male), years in practice (4-25), practice type/size, and tumor specialty. Most oncol-
ogists had no experience with PROs, but were able to identify several concepts
appropriate for PRO assessment (e.g., symptoms and functioning). All oncologists
agreed that when treating curable disease, clinical efficacy (overall survival, pro-
gression free survival) and toxicity were the main drivers of clinical decision mak-
ing. In the non-curative setting, all agreed that PRO data, particularly health-re-
lated quality of life data becomes paramount as a driver of treatment decision
making. Some oncologists felt that patient-reported symptoms were on a par with
toxicology, and saw a benefit to supplementing toxicity data with PRO data. All
agreed that patients were the best source of data regarding symptoms and that
many symptomswere consistent across tumor types. Concern over the subjectivity
and interpretability of PROs, however, was expressed and most oncologists stated
a preference for common toxicity criteria and performance status measures (e.g.,
Karnofsky). Most oncologists agreed that clear and concise reports of PRO datawith
clear explanations of the scale used and interpretability of change would increase
their likelihood of reviewing PRO data. CONCLUSIONS: Oncologists prioritize clin-
ical efficacy endpoints in their treatment decision making; however, in the non-
curative setting PRO data becomesmore influential. Improving the interpretability
of PROmeasures could increase the use of PRO data in treatment decisionmaking.
PCN88
ATTITUDES OF YOUNG WOMEN ON HUMAN PAPILLOMA VIRUS VACCINATION
Chopra P, Shah J, Fase B, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: This study evaluated knowledge and attitude towards human papil-
loma virus (HPV) vaccination among women ages 18-24 years and examined pre-
dictors of attitude towards HPV vaccination. METHODS: A cross-sectional, self-
administered questionnaire was delivered to a convenience sample of female
University students in 2009. Questions on knowledge (9 items) and attitude (2
items) were measured using a 5-point Likert scale. The instrument also included
questions on demographics, HPV vaccination status, source of HPV-related infor-
mation, and healthcare professional’s recommendation. For the purpose of mod-
eling, knowledge (yes/no) and attitude (positive/negative) was reduced to a binary
variable. Data was coded and analyzed using SAS v9.2, by conducting descriptive
analyses, chi-square tests and logistic regression. RESULTS: A total of 136 subjects
completed the survey with a response rate of 46.5%. The mean age of the sample
was 20.67(1.78) years with the majority being unmarried (88.97%) and insured
(72.06%). HPV vaccination rate was 11%. Themean summary knowledge score was
4.4 (3.0) with a reliability coefficient of 0.7. Themean summary attitude scorewas
2.7 (1.2) with a reliability coefficient of 0.8. In the logistic regressionmodel, health
care professional’s recommendation to administer HPV vaccine was a significant
predictor of positive attitude towards the vaccine (OR2.886, 95% CI1.186-7.020,
p0.05) after controlling for race, education, age, knowledge, and vaccination
status. CONCLUSIONS: A healthcare professional’s recommendation to consider
the HPV vaccine was a significant predictor of attitude towards the vaccine. Sub-
optimal knowledge and negative attitude towards HPV vaccination underscore the
need for active education and accurate dissemination of information to women
regarding HPV vaccination.
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OBJECTIVES: Inform clinical trial designs with regards to Health Technology As-
sessment (HTA) agencies’ preferences regarding Quality of Life (QoL) measures for
prostate cancer. METHODS: We searched the Centre for Reviews and Dissemina-
tion database and HTA Watch® for any publication by an HTA agency on prostate
cancer and QoL using the search string “prostate cancer ANDQoL OR quality of life.
RESULTS:We identified 19 HTAs. Four HTAs evaluated drug treatments, 14 evalu-
ated procedures and one evaluated screening. The year of publication ranged from
1996 to 2007. UK agencies published eight of the HTAs, including the four evaluat-
ing drugs, a Norwegian agency published three, and agencies in France, Spain and
the US each published two, with the remaining HTA published by a German
agency. The results of the HTA review demonstrate a consensus regarding a lack of
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evidence on QoL and long-term survival for prostate cancer patients, including
those with castration-resistant prostate cancer (CRPC). The HTAs recommend ran-
domized clinical trials with sufficient follow-up to measure benefits in terms of
overall survival. The trials should include QoL measurements to establish trade-
offs between potential adverse events and benefits of treatment. CONCLUSIONS:A
lack of evidence on QoL for prostate cancer patients is largely responsible for an
absence of specific recommendations from HTAs on QoL measures for prostate
cancer. This has created uncertainty regarding HTA agencies’ preferred QoL mea-
sures. Several current randomized clinical trials for CRPCwill advance significantly
the QoL evidence pool for prostate cancer.
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OBJECTIVES: Understand what fatigue and pain-specific PRO instruments are be-
ing used in the most recent clinical trials for recently approved prostate cancer
drugs.METHODS:We searched the ClinicalTrials.gov database. Searcheswere lim-
ited to drugs recently approved by the FDA and EMA (cabazitaxel, docetaxel, de-
garelix, histrelin, bicalutamide, leuprolide, leuprorelin, triptorelin), but not to any
specific prostate cancer stage. The search terms used were “quality of life OR QOL
OR patient reported outcome” (outcome measure) and “prostate cancer” (for con-
dition). Phase I trials were not considered. We supplemented the search with re-
views of EMA or CMDh drug labels for PRO information. The search was validated
with a Medline search using the above limitations and search terms, limited to
articles published since 1 January 1999.RESULTS: 67 clinical trialswith PROs or QoL
were identified, 33 docetaxel, 14 bicalutamide, 13 leuprolide/leuprorelin, 5 degare-
lix, 2 triptorelin and 1 cabazitaxel. The MOTIF trial, to determine the efficacy of
modafinil in alleviating fatigue in PC patients undergoing docetaxel-based chemo-
therapy, was the only trial to assess fatigue. FACIT-F and SOMA were the PRO
instruments used. Two docetaxel trials and the cabazitaxel trials were the only
ones to have used a pain-specific PRO, the PPI item from the McGill Pain Question-
naire, to measure this symptom. CONCLUSIONS: Despite the ubiquity of fatigue as
a side effect of both hormonal therapy and chemotherapy for prostate cancer, only
one trial assessed this symptom with a dedicated PRO instrument. Although pain
can be one of themost debilitating symptoms associatedwith prostate cancer, only
three trials used a dedicated PRO instrument to assess this symptom. It is unclear
why more PC trials do not use fatigue and pain-specific PRO instruments.
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OBJECTIVES: To prevent cancer recurrence, each year over 100,000 US women
begin a 5-year course of aromatase inhibitors (AIs) for early-stage breast cancer.
AI-related joint pain (arthralgia) may interfere with patients’ well-being in several
domains. There is no arthralgia measurement tool validated in this population
specifically, and more information is needed about the impact of arthralgia on
patient-reported outcomes (PROs) in these patients. We sought to assess relation-
ships of arthralgia with PROs over the 1st 12 weeks of AI therapy.METHODS: Post-
menopausal female oncology outpatients with early stage breast cancer (N52,
pilot sample of the Breast Cancer Adjuvant Therapy cohort) completed paper sur-
veys prior to AI initiation, and every 2 weeks thereafter for 12 weeks. Pain was
measured in 16 joint locations using a 0-10 numeric rating scale. Baseline covari-
ates included age, comorbidities, existingmajor depressive disorder (PHQ-2), social
support (DUFSS), performance status (ECOG), and menopausal symptoms (FACT-
ES). Time-varying PROs examined included physical function, sleep disturbance,
pain interference, and emotional distress (depression), all of whichweremeasured
using PROMIS static short forms. We used mixed models to analyze arthralgia and
PROs. RESULTS: Mean age was 62 years (SD10). The majority of women had
active performance status (n46) and no major depression (n47) at baseline.
Median worst pain in any joint prior to AI initiation was 1 out of 10 (interquartile
range0-5). Adjusting for baseline covariates, greater arthralgia was associated
with worse physical function (0.09[0.13, 0.04]), greater pain interference
(0.15[0.09,0.20]), and greater emotional distress (0.06[0.01,0.11]) but not
with sleep disturbance (0.01[0.03,0.004]). CONCLUSIONS: These prelimi-
nary findings will be used to develop and validate the Patient-Reported Arthralgia
Inventory, toward improving arthralgia measurement. Our findings contribute to
understanding how arthralgia relates to PROs over the 1st 12 weeks of AI therapy.
Targeted AI adherence interventions will rely on comprehensive longitudinal PRO
information.
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OBJECTIVES: The purposes of this study were to investigate redistribution proper-
ties of EQ-5D-5L and to compare the validity and reliability of each EQ-5D version
for Korean cancer patients. METHODS: Patients visiting one ambulatory cancer
center self-administered the two EQ-5D versions and EORTC QLQ-C30 question-
naire. Redistribution properties are examined between EQ-5D-5L and EQ-5D-3L.
Convergent validity of these two versions was evaluated by comparing EQ-VAS,
ECOG performance status and EORTC QLQ C30 subscales. Discriminant ability was
evaluated based on Shannon index and ceiling effect and test-retest reliability was
evaluated using kappa statistics and intraclass correlation coefficient. RESULTS:
Inconsistent rate was 3.5% between two versions. In convergent validity, EQ-5D-5L
demonstrated similar or higher correlations with EQ-VAS, ECOG performance sta-
tus and EORTC QLQ-C30 compared with EQ-5D-3L. Absolute informativity in EQ-
5D-5L was improved but relative informative is similar to the EQ-5D-3L. Ceiling
effect was decreased from 16.8% in the 3L version to 9.7% in the 5L version. Agree-
ments by Kappa were fair to good in 4 dimensions except usual activities in both
EQ-5D instruments. Intraclass correlation coefficient of EQ-5D-5Lindex was 0.77.
CONCLUSIONS: The EQ-5D-5L version appear a valid and reliable quality of life
instrument in cancer patients. EQ-5D-5L enhanced descriptive richness and dimin-
ished ceiling effect compared with EQ-5D-3L.
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OBJECTIVES: Attachment style, or ability to be self-reliant and trust others, cate-
gorized as secure, preoccupied, dismissing or fearful, is related to health outcomes.
Individuals successfully seeking social support can better cope with negative
events. The attachment style of gay menmay affect their ability to be public about
their sexual orientation and seek support, which could affect their health-related
quality of life (HRQOL). We assessed variation in the attachment style of gay men
with prostate cancer and its relationship with HRQOL. METHODS: Participants
(N91) were from a convenience sample of gaymenwith localized prostate cancer.
HRQOL was measured using the Short Form-36 (SF-36) (v1.0) and the Expanded
Prostate Cancer Index Composite (EPIC); the attachment style was scored using the
Relationship Questionnaire. Differences in attachment style were assessed using
ANOVA. Multiple regressionmodels were run to predict the SF-36 physical (PCS) or
mental (MCS) components. RESULTS: Individuals with dismissing attachment
style had lower social network scores and indicated higher bowel symptom bother,
though their bowel function was higher than that of fearful individuals (p0.05).
Dismissing individuals were more comfortable being public about their sexual ori-
entation than preoccupied individuals; had a higher MCS, but did not differ on PCS
than fearful individuals. After adjusting for demographics, social support, espe-
cially size of social network, predicted the MCS; while bowel functioning, urinary/
sexual bother, and comfort with being public about their sexual orientation pre-
dicted the PCS on the SF-36 (p0.05). CONCLUSIONS: Social network may vary by
attachment style, affecting psychosocial adjustment. Interventions should use at-
tachment style as amarker for limited social support and poor long-termHRQOL to
identify gay men with prostate cancer needing additional assistance.
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BACKGROUND: Bevacizumab has been used in first line NSCLC in Europe since its
regulatory approval in 2007. Bevacizumab has demonstrated significantly improved
survival in randomized phase III trials. However, no HRQoL outcomes have been re-
ported so far. OBJECTIVES: To investigate the comparative HRQoL of bevacizumab-
based therapy versus non-bevacizumab based therapy in 1st line non-squamous
NSCLC in two European countries. METHODS: Data were drawn from the Adelphi
NSCLC Disease Specific Programme, a large cross-sectional study of consecutively
presenting patients in France and Germany in 2010. Physicians provided retrospec-
tive information regarding disease status and treatment patterns, with matched
patients invited to complete a questionnaire including the EQ-5D and FACT-L in-
struments. Propensity scoring methods were used to match the two comparison
groups on confounding variables including age, performance status and time since
diagnosis. A t-test was used to assess the relationship between current treatment
and quality of life. RESULTS: 363 non-squamous patients receiving first line treat-
ment were analysed, of which 132 were currently receiving bevacizumab-based ther-
apy and 231were currently receiving non-bevacizumab-based therapy. The quality of
life scores using the FACT-L instrument (based on thematched samples)were 77.3 for
bevacizumab patients (95% CI 73.7 to 81.0) compared with 74.1 for non-bevacizumab
patients (95% CI 70.9 to 77.33), p0.19. The EQ-5D scores for Progression-Free Survival
were 0.68 for the bevacizumab group (95%CI 0.63 to 0.74) and 0.66 for the comparative
patients (95% CI 0.62 to 0.71), p0.57. CONCLUSIONS: This real-life pilot study shows
that bevacizumab-based therapy does not have any detrimental effect on HRQoL as
measured by the EQ-5D and the FACT-L.
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